Jean-Michel Halimi1,2, Alexandre Persu3,4, Pantelis A Sarafidis5, Michel Burnier6, Daniel Abramowicz7, Bénédicte Sautenet1,2, Rainer Oberbauer8, Francesca Mallamaci9, Gérard London10, Patrick Rossignol11, Grégoire Wuerzner6, Bruno Watschinger8, Carmine Zoccali9. 1. Service de Néphrologie-Immunologie Clinique, CHU Tours, Tours, France. 2. FCRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, François-Rabelais University, Tours, France. 3. Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium. 4. Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. 5. Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece. 6. Service of Nephrology and Hypertension, University Hospital (CHUV), Lausanne, Switzerland. 7. Antwerp University Hospital, Department of Nephrology, and Antwerp University, Belgium. 8. Departement of Nephrology, Medical University of Vienna, Austria. 9. CNR-IFC, Clinical Epidemiology and Pathophysiology of Hypertension and Renal Diseases Unit, Ospedali Riuniti, Reggio Calabria, Italy. 10. FCRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, Manhes Hospital and FCRIN INI-CRCTC, Manhes, France. 11. INSERM, Centre, d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, CHU de Nancy, and FCRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, Vandoeuvre-lès-Nancy, France.
Authors: Nikolaos Pagonas; Frederic Bauer; Felix S Seibert; Maximilian Seidel; Peter Schenker; Stylianos Kykalos; Michael Dürr; Petra Reinke; Nina Babel; Richard Viebahn; Timm H Westhoff Journal: Sci Rep Date: 2019-07-19 Impact factor: 4.379